GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Universal Ibogaine Inc (TSXV:IBO) » Definitions » Net-Net Working Capital

Universal Ibogaine (TSXV:IBO) Net-Net Working Capital : C$-0.02 (As of Jan. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Universal Ibogaine Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Universal Ibogaine's Net-Net Working Capital for the quarter that ended in Jan. 2024 was C$-0.02.

The industry rank for Universal Ibogaine's Net-Net Working Capital or its related term are showing as below:

TSXV:IBO's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 4
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Universal Ibogaine Net-Net Working Capital Historical Data

The historical data trend for Universal Ibogaine's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Ibogaine Net-Net Working Capital Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23
Net-Net Working Capital
Get a 7-Day Free Trial 0.02 - -0.17 -0.01 -0.02

Universal Ibogaine Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.02 -0.02 -0.02 -0.02

Competitive Comparison of Universal Ibogaine's Net-Net Working Capital

For the Biotechnology subindustry, Universal Ibogaine's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Universal Ibogaine's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's Price-to-Net-Net-Working-Capital falls into.



Universal Ibogaine Net-Net Working Capital Calculation

Universal Ibogaine's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Jul. 2023 is calculated as

Net-Net Working Capital(A: Jul. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.313+0.75 * 0+0.5 * 0-3.75
-0-0)/191.719
=-0.02

Universal Ibogaine's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jan. 2024 is calculated as

Net-Net Working Capital(Q: Jan. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.365+0.75 * 0.221+0.5 * 0-3.852
-0-0)/191.794
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Universal Ibogaine  (TSXV:IBO) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Universal Ibogaine Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Universal Ibogaine's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Universal Ibogaine (TSXV:IBO) Business Description

Traded in Other Exchanges
Address
400 3rd Avenue South west, Suite 1470, Calgary, AB, CAN, T2P 4H2
Universal Ibogaine Inc develops a platform of addiction treatment clinics, which use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. It runs addiction clinics it has a research partner clinic in Mexico.
Executives
Ian Rabb Senior Officer

Universal Ibogaine (TSXV:IBO) Headlines

No Headlines